Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., today announced encouraging topline results from its pivotal EPICS-III Phase 2(b)/3 clinical trial of Saroglitazar, a novel dual PPAR alpha/gamma agonist, for adult patients with Primary Biliary Cholangitis (PBC) who had an inadequate response or
Chairman of Zydus Pankaj Patel on Friday said that people are the most valuable asset for any organization. "People are the core to anything you do. The only mantra to succeed in any business is to take care of your people; other things will follow,"
In a significant move to address chronic kidney disease (CKD) complications, Zydus Lifesciences has announced a collaborative research agreement with the Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop an innovative oral medication targeting chronic kidney disease-induced osteoporosis.The partnership will focus on discovering small molecule
